Back to search
Aggressive Fibromatosis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Aggressive Fibromatosis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Aggressive Fibromatosis trials you may qualify forThis study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive…
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patient…
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come ba…
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs),…
This is a multicenter, two-part trial in participants with FAP.
This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis…
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable co…
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipil…